<DOC>
	<DOCNO>NCT01334723</DOCNO>
	<brief_summary>This retrospective study aim quantify relationship 5-alpha-reductase inhibitor ( 5ARI ) adherence / length therapy likelihood acute urinary retention ( AUR ) prostate surgery patient benign prostatic hyperplasia ( BPH ) well economic impact associate medical encounter . The Integrated Health Care Information Solutions ( IHCIS ) database utilized study ( 2000-2006 ) .</brief_summary>
	<brief_title>Demonstrating Clinical Economic Benefit 5 Alpha Reductase Inhibitor Adherence Benign Prostatic Hyperplasia</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>5-alpha Reductase Inhibitors</mesh_term>
	<mesh_term>Dutasteride</mesh_term>
	<mesh_term>Finasteride</mesh_term>
	<criteria>Male age 50 year older diagnostic claim BPH prescription claim 5ARI least 60 day observation period . continuously eligible 6 month prior least 6 month index date . prostate cancer prostaterelated surgical procedure prior index date</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Benign prostatic hyperplasia , enlarge prostate , 5-alpha-reductase inhibitor , adherence , surgery , acute urinary retention</keyword>
</DOC>